J Coll Physicians Surg Pak. 2025 Sep;35(9):1122-1127. doi: 10.29271/jcpsp.2025.09.1122.
ABSTRACT
OBJECTIVE: To compare the efficacy of gabapentin combined with pregabalin in postherpetic neuralgia (PHN) attenuation, focusing on patient-reported outcomes and inflammatory cytokine reduction.
STUDY DESIGN: Single-blinded randomised controlled trial. Place and Duration of the Study: Department of Dermatology, Zhongnan Hospital of Wuhan University, Wuhan, China, from June to December 2022.
METHODOLOGY: A total of 134 consecutive patients diagnosed with PHN were randomly allocated into two groups: gabapentin alone (GB group, n = 67) or a combination of gabapentin and pregabalin (GBP group, n = 67) administered orally for 8 weeks. The outcome measures, including the visual analogue scale (VAS) score, clinical efficacy rate, and serum inflammatory factors, were analysed using the t-test, paired t-test, or χ2 test.
RESULTS: At 8 weeks post-treatment, the VAS score of the GBP group was statistically lower than that of the GB group (t = 22.441, p <0.001). The clinical efficacy rate of the GBP group was statistically higher than that of the GB group (74.6% vs. 56.7%, p = 0.029). The GBP group had significantly lower serum levels of interleukin (IL)-6, IL-1β, and tumour necrosis factor-α (TNF-α) compared to the GB group (p <0.05). No significant differences were observed in adverse effects between the two groups (46.3% vs. 54.8%, χ2 = 0.478, p = 0.489).
CONCLUSION: The combination therapy with gabapentin and low-dose pregabalin could help reduce pain and inflammatory factors.
KEY WORDS: Postherpetic neuralgia, Gabapentin, Pregabalin, Anti-inflammatory, Single-masked, Randomised controlled trial.
PMID:40948158 | DOI:10.29271/jcpsp.2025.09.1122
